Ocubio Taps Industry Titans to Guide Ocular Health Revolution

MIAMI, April 30, 2026 – In a move signaling a significant acceleration of its strategic ambitions, biotechnology firm Ocubio today announced the appointment of two of the ophthalmic industry's most influential figures, James V. Mazzo and Dr. Eric D. Donnenfeld, as Strategic Advisors. The appointments are seen by industry observers as a major validation of Ocubio's mission to pioneer personalized, biologic-based therapies for ocular surface disease and a clear indicator of its intent to scale rapidly.

Mazzo, a veteran executive with a formidable track record of building and leading global ophthalmic giants, will advise on commercial strategy and market expansion. He is joined by Dr. Donnenfeld, a world-renowned ophthalmologist and clinical trial expert, who will guide the company's clinical development and physician adoption initiatives. Together, their expertise forms a powerful combination aimed at navigating the complex journey from promising science to a new standard of patient care.

A Power Play for Market Dominance

The addition of James "Jim" Mazzo brings more than four decades of high-impact commercial leadership to Ocubio. His career is a blueprint for scaling ophthalmic businesses into global powerhouses. During his seven-year tenure as Chairman, President, and CEO of Advanced Medical Optics (AMO), he orchestrated a dramatic turnaround, growing annual sales from $538 million to over $1 billion and executing strategic acquisitions valued at over $3 billion. This transformed AMO into a market leader before its eventual acquisition by Abbott.

Mazzo's extensive resume also includes 22 years in senior roles at Allergan and leadership positions as Global President of Ophthalmic Devices for Carl Zeiss Meditec and Executive Chair of AcuFocus. His deep connections span the industry, including advisory roles for private equity firms like CVC Private Equity and Patient Square Capital, giving Ocubio access to a vast network of potential partners and investors.

In his new advisory capacity, Mazzo is tasked with shaping Ocubio’s strategic growth and U.S. market expansion. His proven ability to build world-class commercial infrastructure will be critical as Ocubio prepares to bring its personalized therapies to a broader market. This move is less an advisory role and more a strategic deployment of one of the industry's most effective commercial architects. While his career includes a 2018 settlement with the SEC related to an insider trading case from years prior, his reputation as a builder of formidable ophthalmic enterprises remains largely unparalleled.

"Jim and Eric bring a powerful combination of strategic, commercial, and clinical expertise,” said Francisco Ballester, CEO of Ocubio, in a statement. “Jim’s experience scaling global ophthalmic businesses... will be instrumental as we expand our reach and continue improving patients’ lives.”

Fortifying Clinical Credibility and Physician Trust

Complementing Mazzo's commercial acumen is the immense clinical authority of Dr. Eric D. Donnenfeld. A founding partner of Ophthalmic Consultants of Long Island and a Clinical Professor of Ophthalmology at New York University, Dr. Donnenfeld is an internationally recognized pioneer in cornea, cataract, and refractive surgery. Named "America's Best Eye Doctor" by Newsweek for three consecutive years, his influence among clinicians is profound.

Dr. Donnenfeld’s experience is particularly relevant to Ocubio’s mission. He has served as a principal investigator in more than 60 FDA clinical studies, including trials for landmark ocular surface disease treatments like Restasis and Xiidra. This deep familiarity with the regulatory and clinical trial landscape provides Ocubio with invaluable guidance as it advances its pipeline.

His role will focus on shaping clinical strategy, overseeing research initiatives, and, crucially, driving physician adoption. Gaining the trust of the medical community is a primary hurdle for any novel therapy. Dr. Donnenfeld, a past president of the American Society of Cataract and Refractive Surgery (ASCRS) and Chief Medical Editor of EyeWorld, is uniquely positioned to bridge that gap. He has been instrumental in developing clinical practice guidelines, including the ASCRS algorithm for managing ocular surface disease, demonstrating a commitment to practical, evidence-based care that will directly inform Ocubio’s physician-partnered model.

"Having leaders of Jim and Eric’s caliber join Ocubio is a meaningful validation of the science and mission we’ve built,” noted Alfonso L. Sabater, MD, PhD, Chief Visionary Officer of Ocubio.

Redefining Care for Ocular Surface Disease

Ocubio operates at the forefront of a major shift in ophthalmology towards personalized medicine. Founded in 2018 out of the University of Miami's prestigious Bascom Palmer Eye Institute, the company is focused on complex ocular surface conditions like severe dry eye, which can be debilitating for patients and challenging to treat with one-size-fits-all pharmaceuticals.

The company's approach centers on biologic-based therapies tailored to the individual. Its pipeline includes an allogeneic, standardized human platelet lysate eye drop known as Ophthalmic Biologic Solution (OB-1), developed under an exclusive license. It is also developing personalized autologous serum eye drops (qASED), which utilize a patient's own blood components, processed through an FDA-certified blood center to ensure quality and consistency. This focus on regenerative and personalized solutions has already attracted early-stage grant funding from the U.S. Department of Defense.

In a market with large pharmaceutical players like Novartis and AbbVie, Ocubio’s differentiation lies in this highly specialized, physician-partnered model. The appointments of Mazzo and Donnenfeld are a clear strategy to leverage this unique scientific foundation and build a scalable business that can compete effectively.

A Calculated Union of Commerce and Clinic

The dual appointments represent a holistic strategy to address the primary challenges facing any emerging biotech: proving clinical value and achieving commercial viability. Mazzo provides the blueprint for building the business engine, while Donnenfeld ensures the engine is powered by rigorous science and clinical acceptance.

This fusion of expertise is designed to create a feedback loop where clinical insights inform commercial strategy and commercial success fuels further research and development. It's a model that acknowledges that in modern medicine, breakthrough science is not enough; it must be accompanied by a robust plan for market access, physician education, and patient delivery.

“At Ocubio, everything we do starts with the patient,” said Victor Perez, MD, Chief Science Officer and Co-Founder of Ocubio. “Bringing Jim Mazzo and Dr. Eric Donnenfeld onto our advisory team reflects our commitment to building a company that is both clinically rigorous and commercially strong. Their guidance will help ensure our personalized therapies reach the physicians and patients who need them most.”

With Mazzo charting the commercial course and Donnenfeld validating the clinical path, Ocubio is making a decisive move to transition from a promising research-oriented firm to a major force in ocular healthcare. The company is betting that this combination of seasoned leadership will be the catalyst needed to redefine the standard of care for millions of patients suffering from ocular surface disease.